U.S. FDA Assessing Capability To Amplify Surveillance Of Indian, Chinese OTC Manufacturers - PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - U.S. FDA is gathering information that will likely help the agency intensify its gaze on Indian and Chinese OTC, nutraceutical and traditional medicine manufacturers that use a registration loophole to export products to the U.S. under less stringent oversight